title: Internal radiation therapy for patients with primary or metastatic hepatic cancer: a review.
abstract: BACKGROUND
  The limited efficacy of current approaches to the treatment of patients with hepatic cancer, including external beam radiation therapy and cytotoxic chemotherapy, has reawakened interest in the use of internal radiation therapy.
  
  
  METHODS
  The authors reviewed series of patients with liver metastases or hepatocellular carcinoma (HCC) treated with 1) interstitial irradiation and direct intratumoral injection of 90Y microspheres, 2) intraarterial infusion of (131)I-Lipiodol, 3) intraarterial infusion of 90Y microspheres, or 4) parenteral administration of radiolabeled monoclonal antibodies.
  
  
  RESULTS
  High dose rate interstitial irradiation with afterloading of (192)Ir resulted in local control of hepatic metastases for a median of 8 months and complete tumor eradication in 2 patients. Direct intratumoral injection of 90Y microspheres reduced the size of 90.6% of tumors and completely destroyed them in 8 patients. Treatment with arterial (131)I-Lipiodol resulted in a 17-92% response rate as well as a case of complete remission of unresectable HCC. It was found to be most effective against small tumors. No response was observed with liver metastases from colorectal carcinoma. Partial response was commonly achieved when patients with unresectable liver metastases or HCC were treated with intraarterial 9OY microspheres. Among four patients whose HCC became resectable following treatment with 90Y microspheres, two cases of complete remission were documented. In a prospective randomized trial, (131)I-antiferritin combined with chemotherapy was no more effective than chemotherapy alone.
  
  
  CONCLUSIONS
  The different approaches to internal radiation therapy that are reviewed in this article represent several ways in which radiation can be selectively targeted to hepatic tumors without undue radiation to the nontumorous liver. However, the efficacy of each of these therapies still needs to be evaluated in randomized controlled trials.
authors.affiliation: Department of Clinical Oncology, the Chinese University of Hong Kong and Prince of Wales Hospital, Shatin.
authors.forename: S
authors.initials: S
authors.lastname: Ho
authors.forename: W Y
authors.initials: WY
authors.lastname: Lau
authors.forename: T W
authors.initials: TW
authors.lastname: Leung
authors.forename: P J
authors.initials: PJ
authors.lastname: Johnson
mesh_terms: D001918:Brachytherapy; D006801:Humans; D007263:Infusions, Parenteral; D007267:Injections; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D008863:Microspheres; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
chemical_list: D007457:Iodine Radioisotopes; D015021:Yttrium Radioisotopes